Paper Details

  1. Home
  2. Paper Details

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.

Author: KomatsuNorio, YasudaHajime, YasudaMutsuko

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Treating non-Hodgkin lymphoma (NHL) with chemotherapy in patients on dialysis is complex. Dialysis can affect how drugs are processed in the body, requiring careful dose adjustments to avoid overdosing or undertreating the cancer. Since many chemotherapy drugs and their breakdown products behave differently during dialysis, it's crucial to carefully plan when to administer medications in relation to dialysis sessions. This study reviews real-world cases of NHL patients on dialysis, offering guidance on drug selection, dosing, and timing of chemotherapy treatment based on the available evidence.
Paper Details　
Original Abstract of the Article :
Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conver...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253291/

データ提供：米国国立医学図書館（NLM）

Navigating the Complexities of Chemotherapy in Hemodialysis Patients with Non-Hodgkin Lymphoma

The treatment of non-Hodgkin lymphoma (NHL) in patients undergoing hemodialysis (HD) presents a unique set of challenges in [the field of hematology and oncology]. This research provides a comprehensive review of chemotherapy regimens for NHL in HD patients, highlighting the complexities of dose adjustments, drug administration timing, and managing potential toxicities. The authors analyzed data from 66 HD patients receiving 71 chemotherapy regimens, summarizing the available evidence and offering recommendations for individual chemotherapeutics. This review serves as a valuable resource for clinicians treating NHL patients with kidney failure.

Precision in Chemotherapy: Tailoring Treatment for Hemodialysis Patients

This review emphasizes the need for precision in chemotherapy regimens for NHL patients undergoing HD. Because many chemotherapy drugs are eliminated by the kidneys, careful dose adjustments are critical to avoid overdosing and toxicities. Additionally, the timing of drug administration in relation to HD sessions must be carefully planned to ensure effective treatment and minimize drug loss. The review's analysis of real-world cases provides invaluable insights into the nuances of chemotherapy management in this complex patient population.

Understanding the Challenges of Cancer Treatment in Kidney Failure

Treating cancer in patients with kidney failure is like navigating a desert with shifting sands. This research sheds light on the unique challenges of chemotherapy management in HD patients, highlighting the importance of careful dose adjustments, precise timing of drug administration, and close monitoring for potential toxicities. The review's insights offer valuable guidance for clinicians navigating the complexities of cancer treatment in this challenging population.

Dr.Camel's Conclusion

Chemotherapy in HD patients with NHL is a complex endeavor. This research acts as a guide for clinicians, illuminating the crucial aspects of dose adjustments, drug administration timing, and managing toxicities. Just as a camel relies on its inherent adaptations to thrive in the desert, clinicians need to be adaptable and precise in their treatment approaches to ensure the best possible outcomes for patients with kidney failure and NHL.

Date :
  1. Date Completed 2021-07-08
  2. Date Revised 2021-07-14
Further Info :

Pubmed ID

33938097

DOI: Digital Object Identifier

PMC8253291

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.